Myelodysplastic Syndrome (MDS): Diagnosis and Treatment (22nd Annual National Conference)
This activity consists of a recorded presentation from 22nd Annual National Conference held in Minneapolis, MN on September 24-26, 2013.
Allogeneic hematopoietic cell transplantation (HCT) is the only treatment for MDS with the potential for cure, but its use has been limited by donor availability and the advanced age of most patients with this disorder. However, the advent of reduced-intensity HCT has extended the applicability of HCT to patients in their 60s and even early 70s. Such intensive therapies are preferred in this patient group because of a low expected median survival and high rate of transformation to acute myeloid leukemia when these patients are treated with supportive care alone. This presentation will describe common presentations of MDS, optimal diagnostic approaches, and the role of HCT for MDS and its survival outcomes.
At the end of this educational activity, participants should be able to
- Compare the difference between high- and low-risk MDS and the treatment guidelines for these patients
- Discuss therapy related MDS
- Explain the role of hematopoietic cell transplantation for MDS and its survival outcomes
Aaron T. Gerds, MD, MS
Assistant Professor of Medicine
Cleveland Clinic Learner College of Medicine;
Associate Staff Physician
Department of Hematologic Oncology and Blood Disorders
Cleveland Clinic Taussig Cancer Institute
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or their spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control.
OptumHealth Education ensures that the content is independent of commercial bias.
|Financial Relationship Key|
G- Grant/Research Support
I-Stocks and Other Ownership Interests
O-Other Financial or Material Support
N-Nothing to disclose
UnitedHealth Group (E) (I)
UnitedHealth Group (E) (I)
Method of Participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Participants will receive a certificate upon successful completion of the activity, which includes the following:
- Completing the entire activity
- Completing the Pre- and Post-Activity Assessments, Activity Evaluation, and Application for Certificate of Credit forms
You must be logged into your account to participate in this activity. Get started by clicking “Begin” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save, or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under “My Account”, “My Activities.”
Method for Calculating CE Credit
CE credit was calculated by the complexity of content.
This activity is provided by OptumHealth Education.
There was no commercial support received for this activity.
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software prior to the beginning of this activity.
This activity is designed to meet the educational needs of physicians, nurses, case managers, and other healthcare professionals.
- 1.00 AMA
- 1.00 ANCC
- 1.00 Attendance
- 1.00 CCMC - General